Rocky Mountain MS Research Group Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2012
NCT01569451
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Rocky Mountain MS Research Group, LLC

Active Ingredients

Drugs in Phase 4 Trials (3)

loperamide (imodium) (1 trial)

peanut (1 trial)

simethicone (IMODIUM) (1 trial)

Drugs in Phase 2 Trials (2)

glatiramer acetate (copaxone) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 5